Repligen RGEN Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value at other companies
Other financials
Where this comes from
Reported directly by Repligen in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.
The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Repligen's share based compensation arrangement by share based payment award equity instruments other than options grants in period weighted average grant date fair value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Repligen's share based compensation arrangement by share based payment award equity instruments other than options grants in period weighted average grant date fair value?
- Repligen (RGEN) reported share based compensation arrangement by share based payment award equity instruments other than options grants in period weighted average grant date fair value of $129.34 in Q1 2026.
- What does share based compensation arrangement by share based payment award equity instruments other than options grants in period weighted average grant date fair value mean?
- The weighted-average fair value per share of non-option equity instruments, such as restricted stock units, at the time of their grant. This value is used to determine the total compensation expense to be recognized over the vesting period for these specific awards. It allows investors to gauge the cost-per-unit of non-option equity-based compensation programs.